Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Equity (2016 - 2025)

Sangamo Therapeutics has reported Return on Equity over the past 15 years, most recently at 30.64% for Q4 2025.

  • Quarterly results put Return on Equity at 30.64% for Q4 2025, up 3380.0% from a year ago — trailing twelve months through Dec 2025 was 30.64% (up 3380.0% YoY), and the annual figure for FY2025 was 28.92%, down 2706.0%.
  • Return on Equity for Q4 2025 was 30.64% at Sangamo Therapeutics, up from 8.43% in the prior quarter.
  • Over the last five years, Return on Equity for SGMO hit a ceiling of 30.64% in Q4 2025 and a floor of 8.43% in Q3 2025.
  • Median Return on Equity over the past 5 years was 0.67% (2022), compared with a mean of 0.78%.
  • Biggest five-year swings in Return on Equity: plummeted -551bps in 2024 and later skyrocketed 3380bps in 2025.
  • Sangamo Therapeutics' Return on Equity stood at 0.46% in 2021, then plummeted by -40bps to 0.64% in 2022, then crashed by -272bps to 2.37% in 2023, then plummeted by -34bps to 3.16% in 2024, then soared by 1068bps to 30.64% in 2025.
  • The last three reported values for Return on Equity were 30.64% (Q4 2025), 8.43% (Q3 2025), and 5.17% (Q2 2025) per Business Quant data.